Cargando…

Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers

Objective: Delayed-release mesalamine 400 mg capsules containing four 100 mg tablets have been developed for children with ulcerative colitis who have difficulty swallowing. Bioavailability of the mesalamine capsules was compared with existing mesalamine tablets in healthy adults, and the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakate, Abhijeet, McNamee, Brian, Burkindine, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636446/
https://www.ncbi.nlm.nih.gov/pubmed/31372067
http://dx.doi.org/10.2147/CPAA.S193191
_version_ 1783436063986941952
author Jakate, Abhijeet
McNamee, Brian
Burkindine, Donald
author_facet Jakate, Abhijeet
McNamee, Brian
Burkindine, Donald
author_sort Jakate, Abhijeet
collection PubMed
description Objective: Delayed-release mesalamine 400 mg capsules containing four 100 mg tablets have been developed for children with ulcerative colitis who have difficulty swallowing. Bioavailability of the mesalamine capsules was compared with existing mesalamine tablets in healthy adults, and the effect of food on bioavailability from mesalamine capsules was determined. Tablet swallowability in healthy children was evaluated. Methods: In the open-label, replicate-treatment, single-dose, crossover, comparative bioavailability study, healthy adult volunteers were randomized to one of four treatment sequences to receive mesalamine 400 mg tablets (fasted) twice, mesalamine 400 mg capsules (fasted) twice, and a mesalamine 400 mg capsule (with food) once, with ≥7 days between treatments. Pharmacokinetic (PK) parameters were calculated and analyzed using the reference-scaled average bioequivalence procedure. In the open-label, single-dose swallowability study, healthy children aged 5–11 years were asked to swallow eight placebo tablets identical to those contained in two mesalamine capsules. Results: In the bioavailability study (n=160), mesalamine capsules and tablets in fasted volunteers exhibited similarly delayed absorption and were shown to be bioequivalent; statistical parameters calculated from PK values met the criteria for bioequivalence. A slight increase in mesalamine bioavailability was observed with food administration, but the delayed-release performance of the capsules was not affected. Overall safety profiles between capsules and tablets were similar. In the swallowability study (n=60), the majority of children swallowed eight placebo tablets, with slight variability between age groups. Conclusion: Evaluation of PK parameters confirmed mesalamine capsules are bioequivalent to mesalamine tablets. Mesalamine capsules were well tolerated, can be administered with or without food, and are an age-appropriate product for children.
format Online
Article
Text
id pubmed-6636446
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66364462019-08-01 Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers Jakate, Abhijeet McNamee, Brian Burkindine, Donald Clin Pharmacol Original Research Objective: Delayed-release mesalamine 400 mg capsules containing four 100 mg tablets have been developed for children with ulcerative colitis who have difficulty swallowing. Bioavailability of the mesalamine capsules was compared with existing mesalamine tablets in healthy adults, and the effect of food on bioavailability from mesalamine capsules was determined. Tablet swallowability in healthy children was evaluated. Methods: In the open-label, replicate-treatment, single-dose, crossover, comparative bioavailability study, healthy adult volunteers were randomized to one of four treatment sequences to receive mesalamine 400 mg tablets (fasted) twice, mesalamine 400 mg capsules (fasted) twice, and a mesalamine 400 mg capsule (with food) once, with ≥7 days between treatments. Pharmacokinetic (PK) parameters were calculated and analyzed using the reference-scaled average bioequivalence procedure. In the open-label, single-dose swallowability study, healthy children aged 5–11 years were asked to swallow eight placebo tablets identical to those contained in two mesalamine capsules. Results: In the bioavailability study (n=160), mesalamine capsules and tablets in fasted volunteers exhibited similarly delayed absorption and were shown to be bioequivalent; statistical parameters calculated from PK values met the criteria for bioequivalence. A slight increase in mesalamine bioavailability was observed with food administration, but the delayed-release performance of the capsules was not affected. Overall safety profiles between capsules and tablets were similar. In the swallowability study (n=60), the majority of children swallowed eight placebo tablets, with slight variability between age groups. Conclusion: Evaluation of PK parameters confirmed mesalamine capsules are bioequivalent to mesalamine tablets. Mesalamine capsules were well tolerated, can be administered with or without food, and are an age-appropriate product for children. Dove 2019-07-12 /pmc/articles/PMC6636446/ /pubmed/31372067 http://dx.doi.org/10.2147/CPAA.S193191 Text en © 2019 Jakate et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Jakate, Abhijeet
McNamee, Brian
Burkindine, Donald
Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
title Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
title_full Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
title_fullStr Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
title_full_unstemmed Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
title_short Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
title_sort bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636446/
https://www.ncbi.nlm.nih.gov/pubmed/31372067
http://dx.doi.org/10.2147/CPAA.S193191
work_keys_str_mv AT jakateabhijeet bioavailabilityandswallowabilityofanageappropriatedelayedreleasemesalamineformulationinhealthyvolunteers
AT mcnameebrian bioavailabilityandswallowabilityofanageappropriatedelayedreleasemesalamineformulationinhealthyvolunteers
AT burkindinedonald bioavailabilityandswallowabilityofanageappropriatedelayedreleasemesalamineformulationinhealthyvolunteers